

GLP-1 drugs work better for women, yet most can't get them. Why?

Written by The Life Science Feed Editorial Team · Published 29 September 2026 · Edited by Mara Voss

Women already carry a higher global burden of obesity than men, and they respond to GLP-1 receptor agonists with greater weight loss on average. A Series paper published in *The Lancet Obstetrics, Gynaecology & Women's Health* argues that neither fact has translated into evidence or access built around women's actual needs.¹

KEY TAKEAWAYS

- **The Pivot:** Women carry a higher global obesity burden and respond to GLP-1 drugs with greater weight loss, yet the evidence base and access pathways for these drugs remain built around men by default.
- **The Data:** Nearly 80% of clinically eligible adults live in low- and middle-income countries where GLP-1 drugs can cost over \$90 a month, against a manufacturing estimate under \$5.
- **The Action:** Push for mandatory sex- and ethnicity-stratified reporting in GLP-1 trials, and treat cost as the central, addressable barrier to equitable access rather than a fixed constraint.

The Global Burden of Disease group estimated overweight or obesity affected 46.7% of women and 43.4% of men worldwide in 2021, projected to reach 60.3% and 57.4% by 2050.¹ The gap is widest in low- and middle-income countries, particularly sub-Saharan Africa and south Asia, while some high-income countries see higher male prevalence, a pattern the authors trace to socioeconomic inequality rather than biology alone.

Against that backdrop, GLP-1 receptor agonists have become the default pharmacological response to obesity, and women are already their predominant users. The paper, led by Paul Franks and Claire Meek, sets out where the evidence and the access supporting that use both fall short.¹

Why Women Respond Differently

Weight loss with GLP-1 drugs runs higher in women than men, while glycaemic improvements stay comparable between the sexes.¹ The paper points to higher systemic drug exposure in women that persists even after adjusting for body mass, alongside evidence that women experience stronger suppression of food-motivated behaviour and greater inhibition of palatable food intake on these drugs. Preclinical work has also flagged a possible interaction between GLP-1 signalling and oestrogen, though the mechanism is not established in humans.

Side-effect reporting tells a more complicated story. Real-world data show women reporting headache, vomiting and dizziness at higher rates than men, while placebo-controlled trials show similar rates across sexes, a gap the authors

attribute to reporting behaviour as much as biology and flag as needing dedicated study rather than assumption.

Weight regain after stopping a GLP-1 drug is well documented, and the paper raises a specific concern for women: regained weight tends to be fat without a matching gain in muscle, a pattern with implications for long-term physical function that has not been adequately studied by sex.

The Access Gap

Manufacturing cost estimates put oral semaglutide under \$1 per month and injectable formulations around \$5, yet retail prices across 99 countries analysed exceed \$90 per month in many settings.¹ Nearly 80% of adults who meet clinical eligibility criteria live in low- and middle-income countries, where access remains minimal for women relying on public systems or paying out of pocket.

The paper names a specific, underserved population directly: women with type 2 diabetes in low- and middle-income countries are frequently lean by Western standards, and the BMI threshold at which the disease develops runs lower than in populations of European ancestry, meaning significant weight loss could carry a more pronounced clinical impact in exactly the group least likely to access treatment.

The authors also raise what they term polyendocrine metabolic ovarian syndrome, describing it as an updated name for the condition long known as polycystic ovary syndrome, affecting an estimated 12% of women worldwide with the highest rates in the eastern Mediterranean and southeast Asia. Despite documented benefits from weight loss in this population, GLP-1 drugs are not generally available or centrally funded for this indication in most health systems.

The authors highlight that the current diagnostic criteria for PCOS, which often rely on BMI thresholds derived from Western populations, may further disadvantage women in low- and middle-income countries. These women frequently present with a lower BMI but still experience the metabolic and reproductive sequelae of PCOS, making them less likely to meet conventional treatment criteria for GLP-1 drugs, despite potentially greater relative benefit from weight management. This underscores a critical need for culturally and ethnically sensitive diagnostic and treatment guidelines that reflect the diverse presentations of metabolic conditions globally.

Furthermore, the paper emphasizes the broader implications of this access disparity. Untreated PCOS, particularly when compounded by obesity, significantly increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers. The lack of access to effective interventions like GLP-1 drugs for this population not only perpetuates health inequalities but also places a greater long-term burden on healthcare systems already struggling with resources. Addressing this gap requires a multi-faceted approach, including re-evaluating pricing models, advocating for inclusion in national essential medicines lists, and investing in local manufacturing capabilities where feasible.

The authors also call for more dedicated research into the specific mechanisms underpinning the differential response to GLP-1 drugs between sexes, particularly the potential interaction with oestrogen and its implications for long-term weight management and body composition. Understanding these nuances could lead to personalized treatment strategies,

optimizing outcomes and minimizing side effects for both men and women. Such research should also prioritize diverse populations to ensure findings are generalizable and equitable.

Ultimately, the paper serves as a powerful call to action, urging healthcare professionals, policymakers, and pharmaceutical companies to confront the existing disparities in GLP-1 drug access and research. It highlights that while these medications offer significant promise in combating the global obesity epidemic, their full potential can only be realized when equitable access and tailored treatment approaches are prioritized for all eligible patients, regardless of sex, geography, or socioeconomic status.

CLINICAL IMPLICATIONS

The finding that women lose more weight on these drugs while facing worse access to them is not a paradox, it is the entirely predictable result of a drug class developed and priced without women's specific circumstances built into the process from the start. A hundred-fold gap between manufacturing cost and retail price is not a biological fact about GLP-1 drugs, it is a policy choice, and the paper is right to frame it as the central lever available to close the access gap rather than treating cost as background noise.

For companies and health systems, the call for mandatory sex-stratified and ethnicity-stratified trial reporting is not a bureaucratic add-on. Given documented differences in drug exposure and response between women and men, a trial that does not report results by sex is withholding information clinicians need to prescribe accurately, not just failing an equity standard.

The polyendocrine metabolic ovarian syndrome funding gap deserves specific attention from payers: a condition affecting roughly one in eight women worldwide, with clear evidence that weight loss improves it, sitting outside GLP-1 funding criteria in most systems is a policy gap that outlived the evidence justifying it some time ago.

None of this argues against GLP-1 therapy for women, it argues for building the evidence and the access model to match how these drugs actually behave in women rather than assuming the male-weighted evidence base generalises cleanly. The paper's own framing is the right one: this is a genuine opportunity to improve women's health globally, contingent on treating equitable access as a design requirement rather than an afterthought.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Franks P, Meek CE, et al. GLP-1 receptor agonists and women's health: evidence gaps and equitable access. Presented at: European Association for the Study of Diabetes (EASD) Annual Meeting; September 28-October

2, 2026; Milan, Italy. Forthcoming in The Lancet Obstetrics, Gynaecology & Women's Health. Available from:
[https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038\(26\)00228-1/fulltext](https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00228-1/fulltext)

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** [linkedin.com/company/thelifesciencefeed](https://www.linkedin.com/company/thelifesciencefeed)

thelifesciencefeed.com